title: [Cerebrovascular complications of immunologically mediated heparin-induced thrombocytopenia].
abstract: Immunologically mediated heparin-induced thrombocytopenia (HIT) is a thrombotic disease caused by antibodies occurring after heparin exposure. Thrombocytopenia occurs within a few days after heparin exposure, about half of HIT-patients develop venous or arterial thrombotic complications. Neurological complications of HIT are mainly ischaemic stroke and sinus vein thrombosis. To ensure the primary clinical diagnosis functional and immunological assays for antibody detection are available. The probability for the occurrence of HIT depends on the nature of heparin employed (LMWH vs. UFH) and individual patient characteristics such as gender and primary disease (medical vs. surgical patients). In the case of suspected HIT heparin administration should be discontinued immediately and replaced by an alternative anticoagulation to prevent the expansion or development of further thrombotic complications. Herein we report a case of a patient suffering from HIT-associated embolic cerebral ischaemic stroke.
authors.affiliation: Neurologische Klinik, Universitätsklinikum Erlangen.
authors.forename: K
authors.initials: K
authors.lastname: Macha
authors.affiliation: Neuroradiologische Abteilung, Universitätsklinikum Erlangen.
authors.forename: S
authors.initials: S
authors.lastname: Kloska
authors.affiliation: Neuroradiologische Abteilung, Universitätsklinikum Erlangen.
authors.forename: A
authors.initials: A
authors.lastname: Dörfler
authors.affiliation: Medizinische Klinik 2, Kardiologie und Angiologie, Universitätsklinikum Erlangen.
authors.forename: D
authors.initials: D
authors.lastname: Raaz-Schrauder
authors.affiliation: Neurologische Klinik, Universitätsklinikum Erlangen.
authors.forename: S
authors.initials: S
authors.lastname: Schwab
authors.affiliation: Neurologische Klinik, Universitätsklinikum Erlangen.
authors.forename: M
authors.initials: M
authors.lastname: Köhrmann
authors.affiliation: Neurologische Klinik, Universitätsklinikum Erlangen.
authors.forename: F
authors.initials: F
authors.lastname: Seifert
mesh_terms: D000368:Aged; D000906:Antibodies / Q000032:analysis / Q000276:immunology; D000925:Anticoagulants / Q000009:adverse effects* / Q000737:chemistry; D002545:Brain Ischemia / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000209:etiology*; D017548:Echocardiography, Transesophageal; D006493:Heparin / Q000009:adverse effects* / Q000737:chemistry; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020767:Intracranial Thrombosis / Q000209:etiology / Q000517:prevention & control; D008297:Male; D012851:Sinus Thrombosis, Intracranial / Q000209:etiology; D020521:Stroke / Q000209:etiology; D013921:Thrombocytopenia / Q000139:chemically induced / Q000150:complications* / Q000276:immunology*
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin